Physiogenex is a proud sponsor of the Hanson Wade 7th IPF Summit to be held in Boston, Sept. 19-21, 2023:
On Sept.20th, Dr. François Briand, our Director of Research and Business Development, will be presenting Bleomycin-induced IPF in diet-induced obese (DIO) mice, a novel model to evaluate drugs targeting pulmonary fibrosis.
After his 10-minute oral presentation, François Briand will be presenting the model during a poster session.
Feel free to contact us if you wish to set-up an appointment with Dr. Briand and/or discuss your drug development projects with us.
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.